Seasonal Affective Depression (SAD) Study
Public ClinicalTrials.gov record NCT00069459. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 7 Month, Multicenter, Parallel, Double-Blind, Placebo-Controlled Comparison of 150-300 mg/Day of Extended-Release Bupropion Hydrochloride and Placebo for the Prevention of Seasonal Depressive Episodes in Subjects With a History of Seasonal Affective Disorder Followed by an 8-week Observational Follow-up Phase
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A placebo controlled study evaluating the effectiveness of medication in preventing winter depressive episodes in patients with a history of Seasonal Affective Disorder
Study identification
- NCT ID
- NCT00069459
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 250 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 23, 2003 (Actual)
- Primary completion
- Jun 3, 2004 (Actual)
- Completion
- Jun 3, 2004 (Actual)
- Last update posted
- Sep 25, 2017
2003 – 2004
United States locations
- U.S. sites
- 48
- U.S. states
- 23
- U.S. cities
- 44
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Anchorage | Alaska | 99508 | — |
| GSK Investigational Site | Hamden | Connecticut | 06518 | — |
| GSK Investigational Site | Newark | Delaware | 19713 | — |
| GSK Investigational Site | Wilmington | Delaware | 19808 | — |
| GSK Investigational Site | Washington D.C. | District of Columbia | 20016 | — |
| GSK Investigational Site | Boise | Idaho | 83702 | — |
| GSK Investigational Site | Edwardsville | Illinois | 62025 | — |
| GSK Investigational Site | Hoffman Estates | Illinois | 60194 | — |
| GSK Investigational Site | Northfield | Illinois | 60093 | — |
| GSK Investigational Site | Oak Brook | Illinois | 60523 | — |
| GSK Investigational Site | Oakbrook Terrace | Illinois | 60181 | — |
| GSK Investigational Site | Cedar Rapids | Iowa | 52401 | — |
| GSK Investigational Site | Overland Park | Kansas | 66211 | — |
| GSK Investigational Site | Baltimore | Maryland | 21204 | — |
| GSK Investigational Site | Rockville | Maryland | 20852 | — |
| GSK Investigational Site | Belmont | Massachusetts | 02478 | — |
| GSK Investigational Site | Farmington Hills | Michigan | 48334 | — |
| GSK Investigational Site | Minneapolis | Minnesota | 55454 | — |
| GSK Investigational Site | St Louis | Missouri | 63108 | — |
| GSK Investigational Site | Omaha | Nebraska | 68198 | — |
| GSK Investigational Site | Kenilworth | New Jersey | 07033 | — |
| GSK Investigational Site | Moorestown | New Jersey | 08057 | — |
| GSK Investigational Site | Piscataway | New Jersey | 08854 | — |
| GSK Investigational Site | Princeton | New Jersey | 08540 | — |
| GSK Investigational Site | Albany | New York | 12208 | — |
| GSK Investigational Site | Lawrence | New York | 11559 | — |
| GSK Investigational Site | New York | New York | 10021 | — |
| GSK Investigational Site | New York | New York | 10032 | — |
| GSK Investigational Site | New York | New York | 10128 | — |
| GSK Investigational Site | Rochester | New York | 14618 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45219 | — |
| GSK Investigational Site | Columbus | Ohio | 43210 | — |
| GSK Investigational Site | Lyndhurst | Ohio | 44124 | — |
| GSK Investigational Site | Toledo | Ohio | 43623 | — |
| GSK Investigational Site | Eugene | Oregon | 97401 | — |
| GSK Investigational Site | Portland | Oregon | 97201 | — |
| GSK Investigational Site | Portland | Oregon | 97209 | — |
| GSK Investigational Site | Portland | Oregon | 97210 | — |
| GSK Investigational Site | Allentown | Pennsylvania | 18104 | — |
| GSK Investigational Site | Havertown | Pennsylvania | 19083 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19106 | — |
| GSK Investigational Site | Lincoln | Rhode Island | 02865-4208 | — |
| GSK Investigational Site | Woodstock | Vermont | 05091 | — |
| GSK Investigational Site | Spokane | Washington | 99204 | — |
| GSK Investigational Site | Brown Deer | Wisconsin | 53223 | — |
| GSK Investigational Site | Madison | Wisconsin | 53719 | — |
| GSK Investigational Site | Menomonee Falls | Wisconsin | 53051 | — |
| GSK Investigational Site | Middleton | Wisconsin | 53562-2215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00069459, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 25, 2017 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00069459 live on ClinicalTrials.gov.